Speakers

2025 Expert Speaker Faculty

Take a look at the esteemed speaker faculty for the 7th RAS-Targeted Drug Development Summit.

Haibing Deng, Executive Director, Medicinal Chemistry Abbisko Therapeutics

Haibing Deng

Executive Director
Abbisko Therapeutics

Lauren Stopfer, Executive Director, Proteomics & Innovation, Aethon Therapeutics

Lauren Stopfer

Executive Director, Proteomics & Innovation
Aethon Therapeutics

Soumit Basu, Senior Medical Director, Affini-T Therapeutics

Soumit Basu

Senior Medical Director
Affini-T Therapeutics

Emily Chan, Executive Medical Director, Global Development Lead, Amgen Inc.

Emily Chan

Executive Medical Director, Global Development Lead
Amgen Inc.

Yuliya Katlinskaya, Sr Principal Scientist, Amgen Inc.

Yuliya Katlinskaya

Senior Principal Scientist
Amgen Inc.

Hugh Salter

Chief Scientific Officer
Anocca AB

Katie Smith, Director - Oncology, Arvinas, Inc.

Katie Smith

Director, Oncology
Arvinas, Inc.

Kerstin Sinkevicius, Vice President, Pharmacology, BridgeBio Oncology Therapeutics

Kerstin Sinkevicius

Vice President, Pharmacology
BBOT

Hua Gong, VP, Translational Medicine, BridgeBio Oncology Therapeutics

Hua Gong

Vice President - Translational Medicine
BBOT

Andrew Norris, Senior Director, Research, BCN Biosciences

Andrew Norris

Chief Scientific Officer
BCN Biosciences

Michael Sweeney, Director - Business Development & Operations, Biodesix

Michael Sweeney

Director - Business Development & Operations
Biodesix

Thomas Spires, Senior Director, Translational Medicine, Bristol Myers Squibb

Thomas Spires

Senior Director, Translational Medicine
Bristol Myers Squibb

Cheng Chen, Senior Medical Director, Clinical Lead for KRAS G12C Program, D3 Bio

Cheng Chen

Senior Medical Director, Clinical Lead for KRAS G12C Program
D3 Bio

Jing Zhang, Vice President, Head, Discovery, D3 Blo

Jing Zhang

Vice President, Head, Discovery
D3 Blo

Jia Luo, Thoracic Medical Oncologist and Instructor in Medicine Dana-Farber Cancer Institute, Harvard Medical School

Jia Luo

Thoracic Medical Oncologist and Instructor in Medicine
Dana-Farber Cancer Institute, Harvard Medical School

Pete DeMuth, Chief Scientific Officer, Elicio Therapeutics

Pete DeMuth

Chief Scientific Officer, Founding Scientist
Elicio Therapeutics

Young Su (Bobby) Noh

Director, Head of Onco Clinical Research & Development,
Hanmi Pharmaceuticals

Rebecca Heist, Professor of Medicine Harvard Medical School & Massachusetts General Hospital

Rebecca Heist

Professor
Harvard Medical School & Massachusetts General Hospital

Anita Bellail, Discovery and Development of a Molecular Glue Co-Degrader Targeting KRAS Mutant and CRAF via a Novel E3 Ligase. HB Therapeutics, Inc.

ANITA Bellail

ceo
HB Therapeutics, Inc.

Claudia Beaurivage

Scientific Business Development Manager
HUB Organoids

Brett Hall

Chief Scientific Officer
Immuneering Corporation

Andrea Wang Gillam, Chief Medical Officer & Global Head of Research & Development, Jacobio Pharmaceuticals Inc

Andrea Wang-Gillam

Chief Medical Officer & Global Head of Research & Development
Jacobio Pharmaceuticals Inc

Nicholas Larsen, Senior Director - Biophysics & Structural Biology, Kestrel Therapeutics Inc

Nicholas Larsen

Senior Director - Biophysics & Structural Biology
Kestrel Therapeutics Inc

Ali Smith, Senior Scientist, Kura Oncology

Ali Smith

Senior Scientist
Kura Oncology

Simon Jiang

VP
LIDE Biotech

Aaron Hata, Associate Professor, Massachusetts General Hospital

Aaron Hata

Associate Professor
Massachusetts General Hospital

Eric Haura, Associate Center Director, Clinical Science, Moffitt Cancer Center

Eric Haura

Associate Center Director, Clinical Science
Moffitt Cancer Center

Philip Komarnitsky, Chief Medical Officer, Nested Therapeutics

Philip Komarnitsky

Chief Medical Officer
Nested Therapeutics

Meagan Ryan, Senior Scientist Biology & Translational Sciences, Nested Therapeutics

Meagan Ryan

Senior Scientist - Biology
Nested Therapeutics

Soo-Youl Kim, Chief Executive Officer & Principal Scientist, New Cancer Cure-Bio & National Cancer Center

Soo-Youl Kim

CEO
New Cancer Cure-Bio & National Cancer Center

Shohei Koide, Professor - Biologics Design, New York University Grossman School of Medicine

Shohei Koide

Professor
New York University Grossman School of Medicine

Huaixiang Hao, Co-Founder, Vice President & Head of Research, PAQ Therapeutics

Huaixiang Hao

Head of Research
PAQ Therapeutics

Lan Xu

Senior Vice President, Biology and Translational Medicine
Polymed BioPharma

Myles Walsh

BD
Predicine

Said Sebti, Professor, Virginia Commonwealth University, Founder, Prescient Therapeutics

Said Sebti

Professor
Prescient Therapeutics

Dhirendra Simanshu, Group Lead RAS Initiative, Frederick National Laboratory

Dhirendra Simanshu

Senior Principal Scientist & Group Lead - Structural Biology
RAS Initiative, Frederick National Laboratory

Jingjing Jiang, Vice President, Cancer Pharmacology, Translational Research, Revolution Medicines

Jingjing Jiang

Vice President, Cancer Pharmacology, Translational Research
Revolution Medicines

Ashley Williams, Director - Research & Development, SiVEC Biotechnologies

Ash Williams

Director, Research & Development
SiVEC Biotechnologies

Charly Chahwan, Co-Founder & Chief Scientific Officer, SyntheX

Charly Chahwan

Chief Scientific Officer
SyntheX

Peter Winter, Principal Investigator & Co-Director, Project Ex Vivo The Broad Institute of MIT & Harvard

Peter Winter

Principal Investigator & Co-Director, Project Ex Vivo
The Broad Institute of MIT & Harvard

Andrew Waters, Assistant Professor University of Cincinnati Cancer Center

Andrew Waters

Assistant Professor
University of Cincinnati Cancer Center

Kristen Bryant, Assistant Professor, Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

Kristen Bryant

Assistant Professor, Department of Pharmacology, Lineberger Comprehensive Cancer Center,
University of North Carolina at Chapel Hill

Chiara Ambrogio

Professor Molecular Biotechnology Center
University of Turin

Zhiyong Wang, CSO, Venquis Therapeutics

Zhiyong Wang

Founder & Chief Scientific Officer
Venquis Therapeutics

Silvia Coma, Senior Director, Translational & Preclinical Research, Verastem Oncology

Silvia Coma

Senior Director - Translational & Preclinical Research
Verastem Oncology

Jonathan Pachter, Chief Scientific Officer, Verastem. inc

Jonathan Pachter

Chief Scientific Officer
Verastem. inc

Hui Miao, Senior Scientist, Vividion Therapeutics

Hui Miao

Senior Scientist
Vividion Therapeutics

conference

Explore the Agenda

Hear the latest industry breakthroughs, cutting edge strategies as well as overcome RAS drug bottlenecks during our packed agenda consisting of deep dive workshops, interactive roundtables and data-driven case studies.

View Presentations & Speakers

summit

Partner With Us

Position yourself alongside other leading solution providers to ensure your brand is at the heart of RAS biopharma deals.

Explore Sponsorship Options

conference

Join RAS Experts

Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.